Stay updated on Idasanutlin Combo Therapy in AML Clinical Trial
Sign up to get notified when there's something new on the Idasanutlin Combo Therapy in AML Clinical Trial page.

Latest updates to the Idasanutlin Combo Therapy in AML Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check17 days agoChange DetectedDifference0.2%
- Check24 days agoChange DetectedThe web page has removed significant content regarding a Phase Ib/II study on idasanutlin for treating acute myeloid leukemia, including detailed study descriptions and inclusion/exclusion criteria, while adding a new EudraCT number and a revision number.SummaryDifference10%
- Check32 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check46 days agoChange DetectedDifference0.1%
Stay in the know with updates to Idasanutlin Combo Therapy in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Idasanutlin Combo Therapy in AML Clinical Trial page.